EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access

Real-World Evidence of Automated Insulin Delivery System Use

Elizabeth G Considine iD, Jennifer L Sherr iD

Diabetes Technology & Therapeutics · 2024-03 · 26 (3_suppl) · 53-65

DOI: 10.1089/dia.2023.0442 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Diabetes Technology & Therapeutics, online erschienen am 05.02.2024. Verfasst von Elizabeth G Considine und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin Infusion Systems, Insulin, Hypoglycemic Agents. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Pivotal trials of automated insulin delivery (AID) closed-loop systems have demonstrated a consistent picture of glycemic benefit, supporting approval of multiple systems by the Food and Drug Administration or Conformité Européenne mark receipt. To assess how pivotal trial findings translate to commercial AID use, a systematic review of retrospective real-world studies was conducted.

Methods

PubMed and EMBASE were searched for articles published after 2018 with more than five nonpregnant individuals with type 1 diabetes (T1D). Data were screened/extracted in duplicate for sample size, AID system, glycemic outcomes, and time in automation.

Results

Of 80 studies identified, 20 met inclusion criteria representing 171,209 individuals. Time in target range 70–180 mg/dL (3.9–10.0 mmol/L) was the primary outcome in 65% of studies, with the majority of reports (71%) demonstrating a >10% change with AID use. Change in hemoglobin A1c (HbA1c) was reported in nine studies (range 0.1%–0.9%), whereas four reported changes in glucose management indicator (GMI) with a 0.1%–0.4% reduction noted. A decrease in HbA1c or GMI of >0.2% was achieved in two-thirds of the studies describing change in HbA1c and 80% of articles where GMI was described. Time below range

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Insulin Infusion SystemsInsulinHypoglycemic AgentsBlood GlucoseHumansGlycated HemoglobinAdult

Stichwörter der Autor:innen

Automated insulin deliveryClosed loopReal worldRetrospectiveTime in range

Substanzen

InsulinHypoglycemic AgentsBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, human

Autor:innen und Institutionen

  • Department of Pediatrics, Yale School of Medicine, New Haven, Connecticut, USA.

ORCID-Profile: Elizabeth G Considine, Jennifer L Sherr

Förderung

  • NCATS NIH HHS

Zitieren

APA

Considine, E. G., & Sherr, J. L. (2024). Real-World Evidence of Automated Insulin Delivery System Use. Diabetes Technology & Therapeutics, 26(3_suppl), 53-65. https://doi.org/10.1089/dia.2023.0442

Vancouver

Considine EG, Sherr JL. Real-World Evidence of Automated Insulin Delivery System Use. Diabetes Technology & Therapeutics. 2024;26(3_suppl):53-65. doi:10.1089/dia.2023.0442

BibTeX
@article{Considine2024,
  author = {Considine, Elizabeth G and Sherr, Jennifer L},
  title = {Real-World Evidence of Automated Insulin Delivery System Use},
  journal = {Diabetes Technology & Therapeutics},
  year = {2024},
  volume = {26},
  number = {3_suppl},
  pages = {53--65},
  doi = {10.1089/dia.2023.0442}
}
Kostenlos starten →